MX2019011973A - Uso de la carrimicina y las sales farmaceuticamente aceptables de esta para la preparacion de medicamentos para el tratamiento y/o la prevencion de tumores. - Google Patents

Uso de la carrimicina y las sales farmaceuticamente aceptables de esta para la preparacion de medicamentos para el tratamiento y/o la prevencion de tumores.

Info

Publication number
MX2019011973A
MX2019011973A MX2019011973A MX2019011973A MX2019011973A MX 2019011973 A MX2019011973 A MX 2019011973A MX 2019011973 A MX2019011973 A MX 2019011973A MX 2019011973 A MX2019011973 A MX 2019011973A MX 2019011973 A MX2019011973 A MX 2019011973A
Authority
MX
Mexico
Prior art keywords
cancer
human
cells
carrimycin
tumors
Prior art date
Application number
MX2019011973A
Other languages
English (en)
Inventor
Jiang Enhong
Xia Mingyu
JIANG Xunlei
JIANG Xundong
Original Assignee
Shenyang Fuyang Pharmaceutical Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenyang Fuyang Pharmaceutical Tech Co Ltd filed Critical Shenyang Fuyang Pharmaceutical Tech Co Ltd
Publication of MX2019011973A publication Critical patent/MX2019011973A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

La presente descripción proporciona el uso de la carrimicina y las sales farmacéuticamente aceptables de esta para la preparación de un medicamento para el tratamiento de tumores. La carrimicina y las sales farmacéuticamente aceptables de esta tienen buenos efectos curativos en el cáncer de mama, el cáncer de hígado, el cáncer de pulmón, el cáncer renal, el tumor cerebral, el cáncer cervical, el cáncer de próstata, el cáncer de páncreas, el cáncer de esófago, el adenocarcinoma gástrico, el cáncer de colon, el linfoma o la leucemia y otros tumores, y especialmente tienen efectos inhibitorios obvios en el crecimiento de las células de cáncer de mama humano MCF-7 y MDA-MB-231, las células de hepatoma humano HepG2, las células de cáncer de pulmón de células no pequeñas humano A549, las células de cáncer de pulmón de células grandes humano H460 y H1299, la célula de adenocarcinoma renal de células claras humano 786-O, la célula de adenocarcinoma de células renales humano 769-P y la célula de glioma humano U251.
MX2019011973A 2017-04-06 2018-04-05 Uso de la carrimicina y las sales farmaceuticamente aceptables de esta para la preparacion de medicamentos para el tratamiento y/o la prevencion de tumores. MX2019011973A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710221415 2017-04-06
PCT/CN2018/082072 WO2018184587A1 (zh) 2017-04-06 2018-04-05 可利霉素及其药学上可接受的盐在制备治疗和/或预防肿瘤药物方面的应用

Publications (1)

Publication Number Publication Date
MX2019011973A true MX2019011973A (es) 2019-11-08

Family

ID=63712039

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011973A MX2019011973A (es) 2017-04-06 2018-04-05 Uso de la carrimicina y las sales farmaceuticamente aceptables de esta para la preparacion de medicamentos para el tratamiento y/o la prevencion de tumores.

Country Status (10)

Country Link
US (1) US11077126B2 (es)
EP (1) EP3607952B1 (es)
JP (1) JP6959355B2 (es)
KR (1) KR102327332B1 (es)
CN (1) CN110545820B (es)
AU (1) AU2018247555B2 (es)
CA (1) CA3058935A1 (es)
MX (1) MX2019011973A (es)
RU (1) RU2746047C1 (es)
WO (1) WO2018184587A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2912734T3 (es) * 2017-07-04 2022-05-27 Shenyang Fuyang Pharmaceutical Tech Co Ltd Uso de isovaleril espiramicina I o III en la preparación de fármaco para tratar y/o prevenir el tumor y fármaco
CN110051678B (zh) * 2018-01-19 2022-02-18 沈阳福洋医药科技有限公司 一种预防和/或治疗糖尿病的药物及用途
RU2771046C2 (ru) 2018-01-19 2022-04-25 Шенянг Фуянг Фармасьютекал Технолоджи Ко., Лтд. Применение карримицина или его активных ингредиентов
CN110051679B (zh) * 2018-01-19 2022-02-22 沈阳福洋医药科技有限公司 一种延缓衰老和/或延长寿命的组合物及其用途
US11351185B2 (en) 2020-03-11 2022-06-07 Asclea Corporation Use of isovalerylspiramycins as anti-cancer agents to inhibit metastasis
CN113577086B (zh) * 2020-04-30 2023-05-02 沈阳福洋医药科技有限公司 异戊酰螺旋霉素类化合物或其组合物在制备治疗免疫失调的药物中的应用
CN115551501B (zh) * 2020-05-12 2024-03-22 石药集团中奇制药技术（石家庄）有限公司 一种lsd1抑制剂的用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE82123T1 (de) * 1986-06-06 1992-11-15 Imcera Group Inc Verfahren zum bekaempfen von schweinedysenterie.
CA2127578A1 (en) * 1993-07-08 1995-01-09 Keiichi Ajito 16-membered macrolide derivatives and process for producing the same
JP3023041B2 (ja) * 1993-07-08 2000-03-21 明治製菓株式会社 新規１６員環マクロリド誘導体
CN1058295C (zh) 1997-06-03 2000-11-08 中国医学科学院医药生物技术研究所 一种利用基因工程技术制造生技霉素的方法
JP2004049100A (ja) 2002-07-19 2004-02-19 Meiji Seika Kaisha Ltd ミデカマイシンの生合成遺伝子
CN1169947C (zh) * 2002-11-19 2004-10-06 中国医学科学院医药生物技术研究所 必特螺旋霉素的基因工程菌株螺旋霉素链霉菌wsj-195
CN1237976C (zh) * 2003-12-23 2006-01-25 沈阳同联集团有限公司 必特螺旋霉素及其在抗感染性疾病中的应用
CN101568343A (zh) * 2006-06-12 2009-10-28 雷蒙特亚特特拉维夫大学有限公司 用于治疗癌症的方法
CN102481342A (zh) * 2009-06-24 2012-05-30 S·伊万斯-弗里克 使用促皮质素释放因子治疗癌症的方法
CN101649325B (zh) 2009-07-03 2011-09-07 中国医学科学院医药生物技术研究所 一种提高基因工程异戊酰螺旋霉素主组分含量的基因串连技术
WO2011147316A1 (zh) * 2010-05-25 2011-12-01 沈阳同联集团有限公司 左旋可利霉素、其药物组合物、制备方法及应用
CN102229634B (zh) * 2010-05-25 2014-05-28 沈阳同联集团有限公司 左旋异戊酰螺旋霉素i、其制剂、制备方法及应用
CN102260308B (zh) * 2010-05-25 2014-05-28 沈阳同联集团有限公司 左旋异戊酰螺旋霉素iii、其制剂、制备方法及应用
CN102311471B (zh) * 2010-05-25 2013-10-16 沈阳同联集团有限公司 左旋异戊酰螺旋霉素ii、其制剂、制备方法及应用
CN102115757B (zh) 2010-12-14 2015-10-28 中国科学院南海海洋研究所 台勾霉素的生物合成基因簇及其应用
CN103820474A (zh) 2012-11-16 2014-05-28 中国医药集团总公司四川抗菌素工业研究所 一种多烯多醇大环内脂类化合物的生物合成基因簇
CN103142520B (zh) * 2013-03-15 2015-04-01 沈阳同联集团有限公司 一种可利霉素片及其制备方法
US10363220B2 (en) * 2015-06-03 2019-07-30 Triastek, Inc. Compartmented pharmaceutical dosage forms
CN105505954B (zh) 2015-12-31 2019-01-22 沈阳福洋医药科技有限公司 可利霉素生物合成基因簇
CN105497053B (zh) * 2015-12-31 2018-02-13 沈阳福洋医药科技有限公司 可利霉素在抗结核分枝杆菌感染中的应用

Also Published As

Publication number Publication date
CN110545820B (zh) 2023-01-10
US11077126B2 (en) 2021-08-03
JP6959355B2 (ja) 2021-11-02
AU2018247555A1 (en) 2019-11-21
EP3607952B1 (en) 2022-07-06
CN110545820A (zh) 2019-12-06
KR102327332B1 (ko) 2021-11-17
EP3607952A4 (en) 2020-04-15
US20200030351A1 (en) 2020-01-30
RU2746047C1 (ru) 2021-04-06
EP3607952A1 (en) 2020-02-12
CA3058935A1 (en) 2018-10-11
JP2020516609A (ja) 2020-06-11
KR20190130037A (ko) 2019-11-20
WO2018184587A1 (zh) 2018-10-11
AU2018247555B2 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
MX2019011973A (es) Uso de la carrimicina y las sales farmaceuticamente aceptables de esta para la preparacion de medicamentos para el tratamiento y/o la prevencion de tumores.
AU2015335391B2 (en) Uses of duloxetine HCL medicament in preparing pharmaceutical composition for treatment of cancer
FI3328827T3 (fi) Glutamiinianalogien aihiolääkkeitä
FI3827838T3 (fi) Sytokiini-indusoidun sh2-proteiinin estäminen nk-soluissa
EP3849549A4 (en) POLYTHERAPY FOR THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
RU2018102078A (ru) Комбинированная терапия противоопухолевым алкалоидом
JP2015520753A5 (es)
NZ580009A (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
WO2017091837A3 (en) Therapeutic agents containing cannabis flavonoid derivatives targeting kinases, sirtuins and oncogenic agents for the treatment of cancers
JP2016538344A5 (es)
PH12016502354A1 (en) Pharmaceutical composition
AU2016256469A8 (en) Methods for treating cancer
MX2020011778A (es) Anticuerpos para el tratamiento del cancer.
NZ726365A (en) Combinations for treating cancers
RU2014108042A (ru) Фармацевтическая композиция для лечения и профилактики злокачественной опухоли
YU77601A (sh) Derivati 6-alkenil, 6-alkinil i 6-epoksi-epotilona, postupak za njihovu proizvodnju i njihova upotreba u farmaceutskim pripravcima
RU2014108049A (ru) Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
EA201590694A1 (ru) Ly75 как мишень для терапии и диагностики злокачественных опухолей
PH12020551853A1 (en) Axl kinase inhibitors and use of the same
RU2020102713A (ru) Применение изовалерил-спирамицина i, ii и/или iii при изготовлении препарата для лечения и/или профилактики опухоли и получения лекарственного препарата
EP3705474A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF ACUTE MYELOIC LEUKEMIA OR METASTATIC BREAST CANCER
MX2016002795A (es) Compuestos de triazolona y usos de los mismos.
EP3831412A4 (en) TREATMENT OF METASTATIC BRAIN TUMOR BY ADMINISTRATION OF AN ANTIBODY-DRUG CONJUGATE
MX2022009612A (es) Combinacion de bi853520 con farmacos quimioterapeuticos.
WO2012009663A3 (en) New compounds for treating cancer and other diseases